{"id":"apd356","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2095211","moleculeType":"Small molecule","molecularWeight":"232.15"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By activating CB2 receptors, APD356 is thought to modulate the immune response and potentially reduce inflammation. This mechanism may be beneficial in treating various inflammatory conditions.","oneSentence":"APD356 is a selective agonist of the cannabinoid receptor type 2 (CB2).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:42.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT03266939","phase":"PHASE1","title":"Rebalancing the Serotonergic System in Cocaine Dependence","status":"WITHDRAWN","sponsor":"Mclean Hospital","startDate":"2018-10-04","conditions":"Cocaine Dependence","enrollment":""},{"nctId":"NCT04572243","phase":"PHASE3","title":"A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2020-09-23","conditions":"Epilepsies, Myoclonic","enrollment":22},{"nctId":"NCT06090461","phase":"","title":"Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)","status":"COMPLETED","sponsor":"Currax Pharmaceuticals","startDate":"2014-09","conditions":"Obesity","enrollment":31889},{"nctId":"NCT02400359","phase":"PHASE4","title":"Lorcaserin in Obesity: Identification of CNS Targets Using FMRI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2014-10","conditions":"Obesity, Weight Loss","enrollment":40},{"nctId":"NCT04457687","phase":"","title":"Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies","status":"AVAILABLE","sponsor":"Eisai Inc.","startDate":"","conditions":"Epilepsies, Myoclonic, Drug Resistant Epilepsy","enrollment":""},{"nctId":"NCT03353220","phase":"PHASE4","title":"Predictors of Lorcaserin-Induced Weight Loss","status":"TERMINATED","sponsor":"Columbia University","startDate":"2018-01-03","conditions":"Overweight and Obesity","enrollment":32},{"nctId":"NCT03192995","phase":"PHASE2","title":"Treatment With Lorcaserin for Cocaine Use: The TLC Study","status":"TERMINATED","sponsor":"Glenn-Milo Santos","startDate":"2018-01-01","conditions":"Cocaine Use Disorder","enrollment":22},{"nctId":"NCT00828581","phase":"PHASE1","title":"Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-10","conditions":"Obesity","enrollment":24},{"nctId":"NCT04396834","phase":"PHASE2","title":"Mechanisms of Lorcaserin for Smoking Cessation","status":"TERMINATED","sponsor":"The Mind Research Network","startDate":"2019-12-04","conditions":"Tobacco Use Disorder, Smoking Cessation","enrollment":3},{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":"Obesity","enrollment":200},{"nctId":"NCT04396847","phase":"PHASE2","title":"Laboratory Screening of Lorcaserin for Alcohol Use Disorder","status":"TERMINATED","sponsor":"The Mind Research Network","startDate":"2019-10-25","conditions":"Alcohol Use Disorder, Tobacco Smoking","enrollment":5},{"nctId":"NCT03253926","phase":"PHASE1, PHASE2","title":"Effect of Lorcaserin on Cannabis Withdrawal and Self-administration","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2017-09-05","conditions":"Cannabis Use","enrollment":15},{"nctId":"NCT03720574","phase":"PHASE3","title":"Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients","status":"TERMINATED","sponsor":"Kanion & Huawe Medicine Co.,Ltd","startDate":"2019-09-17","conditions":"Obesity","enrollment":100},{"nctId":"NCT03338296","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2017-09-28","conditions":"Obesity","enrollment":278},{"nctId":"NCT02412631","phase":"PHASE2, PHASE3","title":"Addressing Post Cessation Weight Gain","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-06-15","conditions":"Obesity, Smoking Cessation","enrollment":84},{"nctId":"NCT02796144","phase":"PHASE4","title":"MEtformin and Lorcaserin for WeighT Loss in Schizophrenia","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-09","conditions":"Schizophrenia, Schizoaffective Disorder, Overweight","enrollment":71},{"nctId":"NCT03637842","phase":"EARLY_PHASE1","title":"Lorcaserin for Cannabis Use Disorder","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-08-01","conditions":"Cannabis Use Disorder","enrollment":5},{"nctId":"NCT04205071","phase":"PHASE1","title":"Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer","status":"WITHDRAWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2020-11-01","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":""},{"nctId":"NCT03143855","phase":"PHASE1","title":"Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2017-01-30","conditions":"Opioid Abuse, Opioid Dependence, Opioid-Related Disorders","enrollment":32},{"nctId":"NCT03169816","phase":"PHASE2, PHASE3","title":"Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2017-05-25","conditions":"Opioid-use Disorder","enrollment":60},{"nctId":"NCT03007394","phase":"PHASE2","title":"Lorcaserin in the Treatment of Cocaine Use Disorder","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2017-12-19","conditions":"Cocaine-Related Disorders","enrollment":272},{"nctId":"NCT02537873","phase":"PHASE1","title":"Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-07","conditions":"Cocaine Use Disorder","enrollment":29},{"nctId":"NCT03143543","phase":"PHASE1","title":"Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2015-07","conditions":"Cocaine-Related Disorders, Opioid-Related Disorders","enrollment":171},{"nctId":"NCT03011645","phase":"PHASE1","title":"Gene-by-Stress Interactions in Intervention Studies Significance","status":"TERMINATED","sponsor":"Duke University","startDate":"2018-05-24","conditions":"Cardiovascular Diseases","enrollment":7},{"nctId":"NCT02523690","phase":"PHASE1, PHASE2","title":"Evaluating Muscle Weakness Improvement With Lorcaserin in ICU","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2015-12","conditions":"Muscle Weakness, Sepsis","enrollment":5},{"nctId":"NCT03552107","phase":"","title":"Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic","status":"COMPLETED","sponsor":"Scripps Whittier Diabetes Institute","startDate":"2017-04-11","conditions":"Obesity, Weight Loss, Overweight","enrollment":157},{"nctId":"NCT02932215","phase":"PHASE1","title":"Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2016-10","conditions":"Cannabis Use Disorder","enrollment":17},{"nctId":"NCT00603902","phase":"PHASE3","title":"BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-01","conditions":"Obesity","enrollment":4008},{"nctId":"NCT00395135","phase":"PHASE3","title":"BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-11","conditions":"Obesity","enrollment":3182},{"nctId":"NCT00603291","phase":"PHASE3","title":"BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-12","conditions":"Obesity","enrollment":604},{"nctId":"NCT01987427","phase":"PHASE4","title":"A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2013-10-30","conditions":"Chronic Weight Management","enrollment":344},{"nctId":"NCT02022956","phase":"PHASE1","title":"Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2013-12","conditions":"Pharmacokinetics in Obese Adolescents","enrollment":8},{"nctId":"NCT00829140","phase":"PHASE1","title":"To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-11","conditions":"Obesity","enrollment":56},{"nctId":"NCT00828724","phase":"PHASE1","title":"Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-11","conditions":"Obesity","enrollment":24},{"nctId":"NCT00116740","phase":"PHASE2","title":"Safety and Efficacy of APD356 in the Treatment of Obesity","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-06","conditions":"Obesity","enrollment":400},{"nctId":"NCT00828438","phase":"PHASE1","title":"Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-10","conditions":"Renal Impairment","enrollment":40},{"nctId":"NCT00104507","phase":"PHASE2","title":"Safety and Efficacy of APD356 in the Treatment of Obesity","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2004-12","conditions":"Obesity","enrollment":400},{"nctId":"NCT00828659","phase":"PHASE1","title":"Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-12","conditions":"Drug Abuse, Healthy","enrollment":35},{"nctId":"NCT00828932","phase":"PHASE1","title":"Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-08","conditions":"Hepatic Impairment","enrollment":24},{"nctId":"NCT02019264","phase":"PHASE4","title":"A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2014-01-24","conditions":"Cardiovascular Disease, High Cardiovascular Risk, Obesity","enrollment":14673},{"nctId":"NCT02906644","phase":"PHASE2","title":"Combination Nicotine Patch / Lorcaserin for Smoking Cessation","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11-08","conditions":"Nicotine Dependence","enrollment":97},{"nctId":"NCT02044874","phase":"PHASE2","title":"A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation","status":"COMPLETED","sponsor":"Arena Pharmaceuticals","startDate":"2014-03","conditions":"Smoking Cessation","enrollment":603},{"nctId":"NCT03812523","phase":"PHASE2","title":"Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Southeastern Regional Medical Center","startDate":"2019-06","conditions":"Chemotherapy-Induced Peripheral Neuropathy","enrollment":50},{"nctId":"NCT03741010","phase":"","title":"Belviq Tablet® Post Marketing Surveillance Protocol","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-02-02","conditions":"Weight Loss","enrollment":3000},{"nctId":"NCT03627936","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-08-07","conditions":"Healthy Participants","enrollment":40},{"nctId":"NCT02388568","phase":"NA","title":"Lifestyle Modification and Lorcaserin for Weight Loss Maintenance","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2015-01","conditions":"Obesity","enrollment":137},{"nctId":"NCT02393547","phase":"PHASE1, PHASE2","title":"Lorcaserin for Preventing Weight Gain Among Smokers","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-09","conditions":"Tobacco Use Disorder, Weight Gain","enrollment":20},{"nctId":"NCT02393599","phase":"PHASE1","title":"Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2015-05","conditions":"Cocaine Abuse","enrollment":20},{"nctId":"NCT02129608","phase":"PHASE3","title":"Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-06","conditions":"Overweight, Obese","enrollment":44},{"nctId":"NCT02680288","phase":"PHASE1, PHASE2","title":"Lorcaserin Intra Venous Cocaine Effects","status":"UNKNOWN","sponsor":"Midwest Biomedical Research Foundation","startDate":"2015-11","conditions":"Cocaine Use Disorders","enrollment":32},{"nctId":"NCT02192515","phase":"PHASE1","title":"A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2014-07","conditions":"Healthy Subjects","enrollment":40},{"nctId":"NCT02398669","phase":"PHASE1","title":"A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2015-03","conditions":"Obesity","enrollment":10},{"nctId":"NCT01962402","phase":"PHASE4","title":"Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study","status":"UNKNOWN","sponsor":"Southern California Institute for Research and Education","startDate":"2014-01","conditions":"Weight Gain","enrollment":15},{"nctId":"NCT01880502","phase":"PHASE1","title":"Pharmacokinetic Study of Belviq in Adult Korean Volunteers","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-06","conditions":"Healthy","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"APD356","genericName":"APD356","companyName":"Eisai Inc.","companyId":"eisai-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APD356 is a selective agonist of the cannabinoid receptor type 2 (CB2). Used for Multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}